Genetic testing in breast cancer: who, what and why?

• Date :
• 8    
  0

Can anthracyclines be omitted in TNBC?

• Date :
• 6    
  0

Highlights from the St. Gallen Consensus Panel

• Date :
• 2    
  4

Emerging agents in HR+ breast cancer

• Date :
• 1    
  0

Genomic testing in early breast cancer: MammaPrint & BluePrint

• Date :
• 1    
  0

Key topics at St. Gallen 2021

• Date :
• 1    
  0

St. Gallen international consensus on the optimal primary treatment of women with breast cancer

• Date :
• 1    
  0

How can genomics inform treatment approaches in TNBC?

• Date :
• 1    
  0

Improving access and population-based screening in Europe

• Date :
• 0    
  0

Omitting axillary lymph node dissection in breast cancer patients after neoadjuvant chemotherapy

• Date :
• 0    
  0

The potential of circulating cell-free DNA as a breast cancer biomarker

• Date :
• 0    
  0

Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer

• Date :
• 0    
  0

St. Gallen Consensus 2021: neoadjuvant and adjuvant therapy for HER2+ breast cancer

• Date :
• 0    
  0

Patient advocates at St. Gallen 2021

• Date :
• 0    
  0

Telemedicine in oncology following the COVID-19 pandemic

• Date :
• 0    
  0

Novel therapies for HER2+ metastatic breast cancer

• Date :
• 0    
  0

Cardiac toxicity in patients with breast cancer

• Date :
• 0    
  0

Circulating tumor cell count-driven vs clinician-driven 1L therapy in HR+, HER2- breast cancer

• Date :
• 0    
  0

Identifying novel predictive biomarkers in breast cancer

• Date :
• 0    
  0

Key debates from the St Gallen Expert Consensus

• Date :
• 0    
  0

Will genomic profiling replace clinical and pathological risk factors in ER+ breast cancer?

• Date :
• 0    
  0

Focus of the Oncoplastic Breast Consortium

• Date :
• 0    
  0

Upcoming research into brain metastases in breast cancer

• Date :
• 0    
  0

Key takeaways from the St. Gallen Consensus Panel

• Date :
• 0    
  0

Ultrasound-guided cryoablation in older non-resected breast cancer patients

• Date :
• 0    
  0

Combined analyses of PD-L1 and TILs for therapy selection in TNBC

• Date :
• 0    
  0

The future of global breast cancer care

• Date :
• 0    
  0

Impact of the COVID-19 pandemic on primary endocrine treatment

• Date :
• 0    
  0

Improving global breast cancer treatment guidelines

• Date :
• 0    
  0

Access to therapies in South Africa for patients with breast cancer

• Date :
• 0    
  0

5-year DMFS outcomes in the NBREaST II trial

• Date :
• 0    
  0

Two-phased strategy for the improvement of breast cancer care in Bangladesh

• Date :
• 0    
  0

Optimizing breast cancer care in low- and middle- income countries

• Date :
• 0    
  0

Improving access to endocrine therapies in Mexico

• Date :
• 0    
  0

Tackling residual disease in breast cancer

• Date :
• 0    
  0

Global significance of virtual meetings

• Date :
• 0    
  0

Breast cancer surveillance in PTEN hamartoma tumor syndrome

• Date :
• 0    
  0

The FLEX database is expediting genomic discoveries in breast cancer

• Date :
• 0    
  0

Assessing the global impact of the COVID-19 pandemic on patients receiving breast cancer care

• Date :
• 0    
  0

Cell-free DNA analysis for breast cancer

• Date :
• 0    
  0

Prognostication using germline risk variants and RNA expression for breast cancer

• Date :
• 0    
  0

Sequencing novel HER2-targeted therapies in metastatic breast cancer

• Date :
• 0    
  0

Diagnostic challenges in PTEN hamartoma tumor syndrome

• Date :
• 0    
  0

monarchE: patient-reported outcomes

• Date :
• 0    
  0

St. Gallen Consensus highlights: ovarian suppression, oligometastatic disease and radiotherapy

• Date :
• 0    
  0

Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer?

• Date :
• 0    
  0

The latest treatment options for BRCA-mutated breast cancer

• Date :
• 0    
  0

APHINITY: 6-year follow-up results of dual HER2 blockade in HER2+ breast cancer

• Date :
• 0    
  0

Time for change: introducing genomic predictors in ER+ breast cancer

• Date :
• 0    
  0

EUROPA: endocrine therapy or partial breast irradiation for older women with breast cancer

• Date :
• 0    
  0

The St. Gallen Consensus Session: loco-regional treatment

• Date :
• 0    
  0

Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico

• Date :
• 0    
  0

Encouraging developments in triple negative breast cancer immunotherapy

• Date :
• 0    
  0

ABP 980, a trastuzumab biosimilar in combination with pertuzumab

• Date :
• 0    
  0

HER2CLIMB: tucatinib efficacious against brain metastases in patients with HER2+ breast cancer

• Date :
• 0    
  0

Breast reconstruction and radiation therapy consensus from AIRO

• Date :
• 0    
  0

Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER

• Date :
• 0    
  0

Diagnostic value of methylation signatures in breast cancer

• Date :
• 0    
  0

Treating patients with metaplastic breast cancer

• Date :
• 0    
  0

Real-world outcomes of HER2+ and TNBC patients recieving neoadjuvant chemotherapy

• Date :
• 0    
  0

Metaplastic vs. TNBC: comparing long-term outcomes

• Date :
• 0    
  0

Epidemiological and clinical characteristics of breast cancer in Tunisia

• Date :
• 0    
  0

Mathematical modelling to predict recurrence periods for secondary metastases in breast cancer

• Date :
• 0    
  0

Can we prevent brain metastases in breast cancer?

• Date :
• 0    
  0

Tamoxifen reduced breast cancer risk in chest-irradiated cancer survivors

• Date :
• 0    
  0

Has the COVID-19 pandemic impacted breast cancer treatment access?

• Date :
• 0    
  0

Treatment advances in TNBC

• Date :
• 0    
  0

Key updates from the St Gallen Consensus Session

• Date :
• 0    
  0

Breast surgery de-escalation: can we omit surgery altogether?

• Date :
• 0    
  0

CDK4/6 inhibitors in ER+ metastatic breast cancer during the COVID-19 pandemic

• Date :
• 0    
  0

Landscape of breast cancer services in Europe

• Date :
• 0    
  0

Escalation of adjuvant therapy in HR+ breast cancer

• Date :
• 0    
  0

Prognostic biomarkers in breast cancer – the latest developments

• Date :
• 0    
  0

monarchE: adjuvant abemaciclib in HR+ breast cancer

• Date :
• 0    
  0

Axillary surgery de-escalation in node-positive breast cancer

• Date :
• 0    
  0

The meaning of residual disease in breast cancer

• Date :
• 0    
  0

CALGB 40601 Alliance: impact of dual HER2 targeting on pCR

• Date :
• 0    
  0

Next-generation antibody-drug conjugates in HER2+ breast cancer

• Date :
• 0    
  0

Breast surgery - where do we go?

• Date :
• 0    
  0

Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease

• Date :
• 0    
  0

Phase III trial of denosumab for breast cancer risk reduction in BRCA1 carriers

• Date :
• 0    
  0

The CoMPaS exponential growth model: predicting tumor growth and recurrence

• Date :
• 0    
  0

Adiposity and breast cancer risk in the China Kadoorie Biobank

• Date :
• 0    
  0

Role of SPECT/CT in detecting marked lymph nodes and sentinel nodes following neoadjuvant chemo

• Date :
• 0    
  0

Predicting pathological complete response in breast cancer

• Date :
• 0    
  0

Immunotherapy in early-stage TNBC - where do we stand?

• Date :
• 0    
  0

Extensive DCIS and microcalcifications in patients with breast cancer reaching pCR after NAC

• Date :
• 0    
  0

Reflecting on the use of CDK4/6 inhibitors in HR+ breast cancer

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 1853    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 1725    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 1332    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 4499    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 1006    
  0